________________________________________________________________________________________________________________________________

(C) Algeta 2009 - Gillies O'Bryan-TearGillies O’Bryan-Tear to provide leadership
for Algeta’s phase III trial

August 2009. The appointment ends a difficult period for Algeta.

 

 

 

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 1page

Full Company License enquire here

Back to section

Related Editorial Articles

Transition Cancer Research Translation
Christof von Kalle, Head of Germany’s National Center for Tumor Diseases on transitions in translational cancer research

Merck Serono on stem cell research: Clear away complete confusion of terms
Bernhard Kirschbaum, today Head of Global Research and Early Development for Merck Serono on stem cell research

Horizon Discovery: Mitigating risks and developing the U.S. business

Bayer AG: New Stakes in Stem Cells
Andreas Busch, responsible for Global Drug Discovery of Bayer AG offers insights for technology as well as business developers and venture capital